Daiichi Sankyo Co. Ltd., of Tokyo, reported results of a prespecified subgroup analysis of 771 cancer patients enrolled in the Phase III Hokusai-VTE study, showing that subjects with either a history of cancer or with active cancer treated with once-daily Factor Xa inhibitor edoxaban had a numerically lower incidence of recurrent symptomatic venous thromboembolism compared to warfarin (3.7 percent vs. 7.1 percent).